

Sarepta Therapeutics to Announce Third Quarter 2015 Financial Results and Recent Corporate Developments on November 5, 2015

CAMBRIDGE, Mass.--(BUSINESS WIRE)--October 27, 2015-- Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-targeted therapeutics, will report third quarter 2015 financial results before the NASDAQ Global Market opens on Thursday, November 5, 2015. Subsequently, at 8:00 a.m., Eastern Time, Edward Kaye, M.D., Sarepta's interim chief executive officer and chief medical officer, and Sandy Mahatme, Sarepta's chief financial officer, will host a conference call to discuss third quarter financial results and to provide a corporate update.

The conference call may be accessed by dialing 866-436-9172 for domestic callers and 630-691-2760 for international callers. The passcode for the call is 41044861. Please specify to the operator that you would like to join the "Sarepta Third Quarter 2015 Earnings Call." The conference call will be webcast live under the investor relations section of Sarepta's website at www.sarepta.com and will be archived there following the call for 90 days. Please connect to Sarepta's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

About Sarepta Therapeutics

Sarepta Therapeutics is a biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare, infectious and other life threatening diseases. The Company is primarily focused on rapidly advancing the development of its potentially disease-modifying Duchenne muscular dystrophy (DMD) drug candidates, including its lead DMD product candidate, eteplirsen, designed to skip exon 51. Sarepta is also developing therapeutics for the treatment of infectious diseases such as drug-resistant bacteria and other rare human diseases. For more information, please visit us at www.sarepta.com.

Internet Posting of Information

We routinely post information that may be important to investors in the 'For Investors'

section of our web site at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.

Source: Sarepta Therapeutics, Inc.

Media and Investors:

Sarepta Therapeutics, Inc.

Ian Estepan, 617-274-4052

iestepan@sarepta.com

W2O Group

Ryan Flinn, 415-946-1059

Mobile: 510-207-7616

rflinn@w2ogroup.com